Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autoinjector Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Inhaled Atropine Sulfate in Healthy Adults

NCT00947596
View directory record Official record
Conditions
Organophosphorus Poisoning
Interventions
atropine sulfate
Drug
Lead sponsor
MicroDose Defense Products L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants

NCT02629744
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Etrolizumab, Prefilled Auto-injector (Rotaject)
Drug · Device
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cypress, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

NCT00809146
View directory record Official record
Conditions
Status Epilepticus
Interventions
Intramuscular route of active treatment, Intravenous route of active treatment
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
Not listed
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Autoinjector in Asthmatics

NCT03099096
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

NCT06908577
View directory record Official record
Conditions
Healthy Participants
Interventions
Tozorakimab, Autoinjector (AI) Device, Accessorised Prefilled Syringe (APFS) Device
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

NCT01036165
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RebiSmart™
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

NCT02986139
View directory record Official record
Conditions
Arthritis, Rheumatoid; Arthritis, Psoriatic
Interventions
Commercial Formulation Etanercept, New Formulation Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • El Cajon, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Autoinjector Device Assessment Study

NCT02349802
View directory record Official record
Conditions
Healthy Subjects
Interventions
Auto-injector with exenatide suspension, Syringe with exenatide suspension
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,052 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ofatumumab with PRF, ofatumumab with AI
Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

NCT02458287
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

NCT02940522
View directory record Official record
Conditions
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • DeLand, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 6, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT02937766
View directory record Official record
Conditions
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

NCT05274087
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

The Multicenter, Open-label, Single-use Autoinjector Convenience Study

NCT00958009
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebidose®
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

NCT06262477
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB800, Actemra
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

NCT06741657
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Litifilimab, AI, OBI, PFS
Drug · Device
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab

NCT05339100
View directory record Official record
Conditions
Healthy Participants Study
Interventions
Anifrolumab, Autoinjector, Accessorized Pre-Filled Syringe
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants

NCT02079545
View directory record Official record
Conditions
Healthy
Interventions
Sirukumab (IV infusion), Sirukumab (SC injection with PFS-U), Sirukumab (SC injection with PFS-AI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants

NCT03913260
View directory record Official record
Conditions
Healthy
Interventions
LY3375880, Buffer Matrix (No LY3375880), Autoinjector (AI), Manual Syringe
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

NCT01764633
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
27,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
326
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

NCT01644474
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Ezetimibe, Placebo (for Alirocumab), Placebo (for Ezetimibe)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 6, 2026, 5:32 PM EDT
Recruiting Phase 3 Interventional

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

NCT07661056
View directory record Official record
Conditions
Graves Disease
Interventions
BHV-1300, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Tucson, Arizona • Burbank, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 6, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen

NCT02097173
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate
Drug
Lead sponsor
medac GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 6, 2026, 5:32 PM EDT